Birdwatch Note Rating
2024-04-17 04:49:57 UTC - NOT_HELPFUL
Rated by Participant: DDCC6A1C7152272E2992AEF9DDCD4DEFD6BF29E8AAE39767E9641AB5BA4870FC
Participant Details
Original Note:
This study is about daily ketamine abusers (2–9.7 years; mean use 2.4 g/day). Esketamine has been approved as a treatment for depression in both the United States and Europe. Low dose ketamine schedules have strong antidepressant effects in depressed patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972190/
All Note Details